The FLIP-side of Fas signaling

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 5929-5931

  Hyer, Marc L ^a   Samuel, Temesgen ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CYCLOHEXIMIDE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SYNAPSIN I; TUMOR NECROSIS FACTOR;

CELL PROLIFERATION; CELL STRAIN HEK293; CROSS LINKING; HUMAN; IMMUNOBLOTTING; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; THYROID CANCER;

ANTIGENS, CD95; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 33750716875     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2098     Document Type: Short Survey

References (36)

1. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
2. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
3. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
4. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
5. Filippatos G, Ang E, Gidea C, Dincer E, Wang R, Uhal BD. Fas induces apoptosis in human coronary artery endothelial cells in vitro. BMC Cell Biol 2004;5:6.
6. Inaba H, Shimada K, Zhou YW, et al. Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1. Int J Oncol 2005;27:573-9.
7. Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-5.
8. Aggarwal BB, Singh S, LaPushin R, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995;364:5-8.
9. Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997;108:215-9.
10. Jelaska A, Korn JH. Anti-Fas induces apoptosis and proliferation in human dermal fibroblasts: differences between foreskin and adult fibroblasts. J Cell Physiol 1998;175:19-29.
11. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000;6:920-3.
12. Mitsiades CS, Poulaki V, Fanourakis G, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006;12:3705-12.
13. Owen-Schaub L, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and Bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
14. Mapara MY, Bargou R, Zugck C, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993;23:702-8.
15. Borset M, Hjorth-Hansen H, Johnsen AC, et al. Apoptosis, proliferation and NF-κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol 1999;63:345-53.
16. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:4122-9.
17. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60.
18. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-70.
19. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35.
20. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
21. Scaffidi C, Smitz I, Krammer PH, Peter ME. The role of c-Flip in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-8.
22. Chang DW, Xing Z, Pan Y, et al. c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002;21:3704-14.
23. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
24. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002;277:45162-71.
25. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001;1:50-8.
26. Peter ME. The flip side of FLIP. Biochem J 2004;382:e1-3.
27. Chau H, Wong V, Chen NJ, et al. Cellular FLICE-inhibitory protein is required for T cell survival and cycling. J Exp Med 2005;202:405-13.
28. Zhang N, He YW. An essential role for c-FLIP in the efficient development of mature T lymphocytes. J Exp Med 2005;202:395-404.
29. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000;10:640-8.
30. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene 2000;19:4451-60.
31. Kreuz S, Siegmund D, Rumpf JJ, et al. NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 166;369-80.
32. Imamura R, Konaka K, Matsumoto N, et al. Fas ligand induces cell-autonomous NF-κB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-α. J Biol Chem 2004;279:46415-23.
33. Bannerman DD, Eiting KT, Winn RK, Harlan JM. FLICE-like inhibitory protein (FLIP) protects against apoptosis and suppresses NF-κB activation induced by bacterial lipopolysaccharide. Am J Pathol 2004;165:1423-31.
34. + T cell activation through caspase-8-dependent NF-κB activation. J Immunol 2005;174:5270-8.
35. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol Cell Biol 2004;24:2627-36.
36. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 1992;10:267-93.